Project Description

An affordable pneumococcal conjugate vaccine after 20 years.

Background: In The Lancet Infectious Diseases, Ed Clarke and colleagues 1 report a phase 3 non-inferiority trial of a new ten-valent pneumococcal polysaccharide protein conjugate vaccine (SIIPL-PCV) developed by Serum Institute of India, done in 2250 healthy infants in The Gambia.

Author List: Madhi SA, Knoll MD.

Journal Name: Lancet Infect Dis. 2021 Jan 28:S1473-3099(21)00002-5. doi: 10.1016/S1473-3099(21)00002-5. Epub ahead of print. PMID: 33516294.

View Details